DECENTRALIZATION AND REGIONALIZATION OF HEALTH ACTIONS AND SERVICES AND THE CORRELATION BETWEEN SDG, IEG-M AND IGM SUS-SP

Resumo

The use of off-label medications, defined as the prescription of drugs for purposes not specified in the label approved by regulatory agencies, is a growing practice in contemporary medicine. This phenomenon is often linked to the lack of alternative therapies or the existence of favorable scientific evidence; however, it raises concerns regarding safety and efficacy. The central issue lies in the judicialization of healthcare, where patients seek access to off-label medications through legal action, burdening the healthcare system and creating complex legal precedents. This study aims to analyze the regulation, challenges, and legal implications of off-label drug use in Brazil, with a comparative analysis between Brazil, the United States, and the European Union. The methodology includes a literature review and documentary analysis of legislation, case law, and scientific studies on the topic. The results indicate that the lack of clear regulation in Brazil contributes to inconsistent and unsafe practices, in addition to intensifying judicialization. In contrast, the United States and the European Union adopt distinct but equally rigorous approaches to the regulation of off-label use. It is concluded that more robust regulation and the establishment of strict criteria for off-label prescriptions may reduce risks and mitigate the negative impacts of judicialization in Brazil, promoting greater safety for patients and healthcare professionals. The differences between the regulatory frameworks of the Brazilian Health Regulatory Agency (ANVISA), the United States Food and Drug Administration (FDA), and the European Medicines Agency (EMA) highlight the need for ongoing debate on the role of regulatory agencies, medical professional autonomy, and patient protection, especially in the face of increasing judicialization of healthcare.